
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is an early-stage biopharmaceutical company that has a positive outlook as it has demonstrated positive interim results in its ongoing Phase 2 trials for Alzheimer's disease, with a high potential in addressing the large market for the disease and achieving significant milestones in mid-2026. Its latest financial results show a slight increase in revenue and a decreasing net loss. The company is also making progress in its other investigational drug candidates and has achieved over 70% patient enrollment in its Phase 2 CALMA trial of IGC-AD1. As a result, the company's current valuation is attractive, with a projected significant upside potential based on a NPV analysis.
Bears say
IGC Pharma is a Maryland-based clinical-stage pharmaceutical company with a negative outlook, as their 5 drug candidates for Alzheimer's disease have only shown potential in Alzheimer's cell lines and their fiscal year change from March to December may introduce accounting discrepancies. Additionally, the Alzheimer's market is highly competitive with no known cure or means of prevention, and the company faces numerous risks to achieving their share price target, including balance sheet and liquidity risks, failure of product candidates in clinical trials, and changing macroeconomic factors.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares